MARLBOROUGH, Mass.,
May 27, 2015 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering and developing innovative therapies
primarily in the areas of dermatology and ophthalmology,
today announced that it has commenced a public offering of
shares of its common stock, warrants to purchase shares of its
common stock and overallotment purchase rights to purchase shares
of its common stock. The shares of common stock, warrants and
overallotment purchase rights are immediately separable and will be
issued separately. All of the shares in the offering are to be sold
by RXi Pharmaceuticals. H.C.
Wainwright & Co., LLC will act as exclusive placement
agent on a best efforts basis for the offering.
Logo- http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
The Company intends to use the net proceeds from this offering
for general corporate purposes, which include, but are not limited
to, funding its ongoing and future clinical trials and for general
and administrative expenses. The Company may also use a portion of
the net proceeds to acquire or invest in complementary businesses,
products and technologies or to fund the development of any such
complementary businesses, products or technologies that it may
acquire in a stock-based acquisition. The Company has no current
plans for any such acquisitions.
The securities described above are being offered by the Company
pursuant to a registration statement on Form S-1, together with a
base prospectus, previously filed with and declared effective by
the Securities and Exchange Commission (SEC). A preliminary
prospectus related to the offering has been filed with the
SEC. When available, copies of the preliminary prospectus may
be obtained from H.C. Wainwright
& Co., LLC, 430 Park Avenue, New
York, New York 10022, via e-mail at placements@hcwco.com or
via telephone at (212) 356-0530.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the areas of dermatology and
ophthalmology that address high-unmet medical needs. Our discovery
and clinical development programs are based on siRNA technology as
well as immunotherapy agents. These compounds include, but
are not limited to, our proprietary, self-delivering RNAi
(sd-rxRNA®) compounds for the treatment of dermal and
retinal scarring. It also includes an immunomodulator, Samcyprone™,
a proprietary topical formulation of diphenylcyclopropenone (DPCP),
for the treatment of such disorders as alopecia areata, warts, and
cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum. We are committed to being a
partner of choice for academia, small companies, and large
multinationals. We welcome ideas and proposals for strategic
alliances, including in- and out-licensing opportunities, to
advance and further develop strategic areas of interest.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-warrants-300089684.html
SOURCE RXi Pharmaceuticals Corporation